A61K 47/6873
The antibody targeting an immunoglobulin
Official title: {the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody}
A61K47/6873 (The antibody targeting an immunoglobulin) appears on 74 US grants and 83 published applications in this corpus.
Search patents in A61K- Granted patents
- 74
- Published applications
- 83
- Assignees
- 55
- Inventors
- 225
- Latest grant
- 8 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 4 | 0 |
| 1994 | 2 | 0 |
| 1995 | 7 | 0 |
| 1996 | 3 | 0 |
| 1997 | 2 | 0 |
| 1998 | 1 | 0 |
| 1999 | 3 | 0 |
| 2000 | 2 | 0 |
| 2001 | 3 | 0 |
| 2002 | 1 | 1 |
| 2003 | 2 | 4 |
| 2004 | 1 | 0 |
| 2005 | 0 | 2 |
| 2006 | 0 | 1 |
| 2007 | 1 | 1 |
| 2008 | 1 | 3 |
| 2009 | 0 | 0 |
| 2010 | 4 | 2 |
| 2011 | 1 | 1 |
| 2012 | 2 | 3 |
| 2013 | 1 | 1 |
| 2014 | 1 | 0 |
| 2015 | 1 | 1 |
| 2016 | 1 | 2 |
| 2017 | 0 | 1 |
| 2018 | 1 | 2 |
| 2019 | 1 | 9 |
| 2020 | 4 | 7 |
| 2021 | 2 | 3 |
| 2022 | 5 | 8 |
| 2023 | 6 | 4 |
| 2024 | 6 | 12 |
| 2025 | 2 | 10 |
| 2026 | 0 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Dual conjugation process for preparing antibody-drug conjugates8 Jul 2025US 12,350,345 B2Byondis B.V.
- Anti-LAG-3 antibodies and methods of use thereof7 Jan 2025US 12,187,795 B2Agenus Inc.
- Chimeric small molecules for the recruitment of antibodies to cancer cells10 Sep 2024US 12,084,517 B2Yale University
- Engineered immunostimulatory bacterial strains and uses thereof18 Jun 2024US 12,012,600 B2Actym Therapeutics, Inc.
- Anti-lag-3 antibodies and methods of use thereof28 May 2024US 11,993,651 B2Agenus Inc.
- Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies13 Aug 2026US 2026/0232834 A1GlaxoSmithKline Intellectual Property Development Limited
- Cycling lysosomal targeting antibody conjugates6 Aug 2026US 2026/0224714 A1Lycia Therapeutics, Inc.
- Lysosomal targeting bifunctional molecules for degradation of autoantibodies6 Aug 2026US 2026/0224719 A1Lycia Therapeutics, Inc.
- Cdh17-binding antibodies and methods of use thereof30 Apr 2026US 2026/0115303 A1Antharis Therapeutics Inc.
- Isolated antigen binding protein and use thereof5 Feb 2026US 2026/0035484 A1Longbio Pharma (Suzhou) Co., Ltd.
Most cited
By later US patents
- Polypeptide variants1,041US 6,194,551 B1Genentech, Inc. · 2001
- Polypeptide variants521US 6,528,624 B1Genentech, Inc. · 2003
- Polypeptide variants405US 6,538,124 B1Genentech, Inc. · 2003
- Methods for determining binding of an analyte to a receptor299US 6,242,195 B1Genentech, Inc. · 2001
- Polypeptide variants104US 7,297,775 B2Genentech, Inc. · 2007